Kline & Specter represents victims of problem pharmaceuticals.

The multiple sclerosis drug Avonex may cause liver failure, according to a warning issued March 16, 2005 by the manufacturer, Biogen Idec Inc., and the U.S. Food and Drug Administration.

Biogen said severe liver injury, including liver failure, was reported in rare cases among patients using Avonex. The company did not remove Avonex from the market but changed its label from carrying an advisory to one bearing a stronger "warning" about possible liver damage.

Avonex has been on the market since 1996 and was used by about 130,000 patients.

If you or someone you know suffered illness or death as a result of using Avonex, you may want to contact an Avonex lawyer.

The warning about Avonex came just weeks after a newer Biogen drug used to treat multiple sclerosis, Tysabri, was suspended from the market after reports that the medication may have caused a rare brain disease in two patients, one of whom died.

Biogen and its partner, Elan Corp., agreed to suspend Tysabri (formerly known as Antegren during clinical trials), while the FDA issued a public health advisory on Feb. 28, 2005 to inform patients and doctors about the potential problem with the prescription drug.

For a free evaluation of your Avonex claim contact our experienced Avonex attorneys. We will evaluate your Avonex lawsuit and help you get the result you deserve.

Avonex News

Biogen Idec
Biogen Idec - Important Drug Warning Letter

New York Times
Biogen and F.D.A. Issue Drug Warning